Nov 27 (Reuters) - Xenon Pharmaceuticals said on Monday its experimental drug to treat severe major depressive disorder had failed to meet the main goal in a mid-stage study. (Reporting by Mariam Sunny in Bengaluru; Editing by Pooja Desai)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
40.45 USD | -0.32% | -5.78% | -12.18% |
May. 10 | Wedbush Trims Xenon Pharmaceuticals' Price Target to $50 From $51, Maintains Outperform Rating | MT |
May. 09 | Xenon Pharmaceuticals Q1 Net Loss Narrows | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-12.18% | 3.05B | |
+7.52% | 113B | |
+11.38% | 106B | |
+1.48% | 22.27B | |
-12.64% | 22.22B | |
-5.10% | 19.43B | |
-37.85% | 17.87B | |
-8.58% | 17.24B | |
+7.77% | 14.29B | |
+37.41% | 12.52B |
- Stock Market
- Equities
- XENE Stock
- News Xenon Pharmaceuticals Inc.
- Xenon Pharmaceuticals' depression drug fails to meet main goal in study